Ascendis Pharma A/S (ASND.OQ)
ASND.OQ on NASDAQ Stock Exchange Global Select Market
63.81USD
20 Apr 2018
63.81USD
20 Apr 2018
Change (% chg)
$-1.20 (-1.85%)
$-1.20 (-1.85%)
Prev Close
$65.01
$65.01
Open
$64.84
$64.84
Day's High
$65.46
$65.46
Day's Low
$63.70
$63.70
Volume
12,676
12,676
Avg. Vol
48,116
48,116
52-wk High
$68.98
$68.98
52-wk Low
$21.95
$21.95
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2017 | Dec '17 | 0.28 | -0.925 |
| Sep '17 | 0.43 | -1.039 | |
| Jun '17 | 0.44 | -0.945 | |
| Mar '17 | 0.37 | -0.775 | |
| FY 2016 | Dec '16 | 1.04 | -0.535 |
| Sep '16 | 1.17 | -0.724 | |
| Jun '16 | 1.14 | -0.528 | |
| Mar '16 | 1.26 | -0.817 |
*Note: Units in Millions ofEuro
**Note: Units in Euro
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 4 | 0.41 | 1.14 | 0.00 | 1.23 |
| Quarter Ending Sep-18 | 4 | 0.41 | 1.14 | 0.00 | 1.23 |
| Year Ending Dec-18 | 6 | 3.16 | 10.00 | 0.80 | 4.29 |
| Year Ending Dec-19 | 5 | 2.73 | 10.00 | 0.00 | 4.17 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 4 | -0.75 | -0.58 | -0.81 | -0.44 |
| Quarter Ending Sep-18 | 4 | -0.75 | -0.58 | -0.81 | -0.44 |
| Year Ending Dec-18 | 6 | -3.14 | -2.35 | -3.45 | -2.71 |
| Year Ending Dec-19 | 5 | -3.21 | -1.72 | -4.05 | -4.15 |
Sales and Profit Figures in Euro (EUR);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 188.22 | 33.60 | |
| P/E High - Last 5 Yrs. | -- | 284.72 | 45.95 | |
| P/E Low - Last 5 Yrs. | -- | 95.76 | 24.93 | |
| Beta | -- | 0.75 | 0.80 | |
| Price to Sales (TTM) | 1,409.55 | 136.15 | 7.07 | |
| Price to Book (MRQ) | 10.26 | 19.54 | 5.13 | |
| Price to Tangible Book (MRQ) | 11.74 | 24.07 | 6.73 | |
| Price to Cash Flow (TTM) | -- | 122.99 | 25.52 | |
| % Owned Institutions | 74.76 | 11.18 | 2.22 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.28 | 1.51 | |
| Dividend Yield - 5 Year Avg | -- | 0.20 | 0.75 | |
| Dividend 5 Year Growth Rate | -- | 1.94 | 3.93 | |
| Payout Ratio(TTM) | -- | 9.18 | 20.35 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -73.15 | 103.73 | 9.02 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -66.78 | 79.72 | 10.83 | |
| Sales - 5 Yr. Growth Rate | -37.14 | 33.87 | 8.21 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | -72.90 | -66.87 | 22.25 | |
| EPS (TTM) vs TTM 1 Yr. Ago | -41.48 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 47.46 | 10.26 | |
| Capital Spending - 5 Yr. Growth Rate | 26.46 | 45.48 | 10.37 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 1.63 | 2.53 |
| Current Ratio (MRQ) | 8.61 | 5.97 | 3.62 |
| LT Debt to Equity (MRQ) | 0.00 | 23.32 | 11.31 |
| Total Debt to Equity (MRQ) | 0.00 | 25.75 | 13.97 |
| Interest Coverage (TTM) | -- | -186.61 | 30.11 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 36.56 | 54.01 | |
| Gross Margin - 5 Yr. Avg. | -- | 55.38 | 52.12 | |
| EBITD Margin (TTM) | -7,242.29 | -- | -- | |
| EBITD - 5 Yr. Avg | -473.06 | -152.18 | 15.89 | |
| Operating Margin (TTM) | -7,290.26 | -563.03 | 4.33 | |
| Operating Margin - 5 Yr. Avg. | -478.97 | -164.18 | 11.25 | |
| Pre-Tax Margin (TTM) | -8,129.02 | -535.84 | 4.97 | |
| Pre-Tax Margin - 5 Yr. Avg. | -477.57 | -171.12 | 11.56 | |
| Net Profit Margin (TTM) | -8,097.84 | -524.81 | 1.58 | |
| Net Profit Margin - 5 Yr. Avg. | -474.67 | -171.01 | 7.89 | |
| Effective Tax Rate (TTM) | -- | -0.44 | 31.30 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 18.14 | 24.27 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 13,721 | 23,887,722 | 816,988,634 | |
| Net Income/Employee (TTM) | -1,111,100 | 956,935 | 96,050,323 | |
| Receivable Turnover (TTM) | 6.44 | 6.24 | 5.56 | |
| Inventory Turnover (TTM) | -- | 2.37 | 3.45 | |
| Asset Turnover (TTM) | 0.01 | 0.40 | 0.89 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -61.79 | -0.77 | 10.54 | |
| Return on Assets - 5 Yr. Avg. | -43.95 | 0.70 | 11.56 | |
| Return on Investment (TTM) | -68.11 | -0.74 | 13.19 | |
| Return on Investment - 5 Yr. Avg. | -52.07 | 4.20 | 14.97 | |
| Return on Equity (TTM) | -68.11 | -2.80 | 15.00 | |
| Return on Equity - 5 Yr. Avg. | -52.07 | -0.05 | 16.25 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -66.78 | -52.17 | -37.14 |
| EPS (TTM) % | -42.88 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Ascendis Pharma A/S
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | -0.79 | -3.84 | 47 | 9 |
| 13 Week | 23.83 | 30.33 | 85 | 72 |
| 26 Week | 81.95 | 75.48 | 91 | 89 |
| 52 Week | 130.61 | 103.47 | 91 | 77 |
| YTD | 59.29 | 59.49 | 89 | 88 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Ascendis Pharma Reports Full Year 2017 Financial Results
- BRIEF-Ascendis Pharma prices 3.9 mln American Depositary Shares At $57 Per ADS
- BRIEF-Ascendis Pharma A/S Announces Proposed Public Offering Of ADSS
- BRIEF-Ascendis Pharma Says Completed Target Enrollment In Phase 3 Trial Of Pediatric Growth Hormone Deficiency Treatment
- BRIEF-Ascendis Pharma Initiates Submissions In Australia To Enter Study With Transcon CNP
Institutional Holders
| % Shares Owned: | 74.79% |
| # of Holders: | 82 |
| Total Shares Held: | 31,097,172 |
| 3 Mo. Net Change: | 400,392 |
| # New Positions: | 3 |
| # Closed Positions: | 1 |
| # Increased Positions: | 6 |
| # Reduced Positions: | 5 |
| # Net Buyers: | 1 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.